The Effect of Geographic Location on Circannual Adrenocorticotropic Hormone Plasma Concentrations in Horses in Australia

C.J. Secombe, R.H.H. Tan, D.I. Perara, D.P. Byrne, S.P. Watts, and J.G. Wearn

Background: Longitudinal evaluation of plasma endogenous ACTH concentration in clinically normal horses has not been investigated in the Southern Hemisphere.

Objectives: To longitudinally determine monthly upper reference limits for plasma ACTH in 2 disparate Australian geographic locations and to examine whether location affected the circannual rhythm of endogenous ACTH in the 2 groups of horses over a 12-month period.

Animals: Clinically normal horses <20 years of age from 4 properties (institutional herd and client owned animals) in Perth (n = 40) and Townsville (n = 41) were included in the study.

Methods: A prospective longitudinal descriptive study to determine the upper reference limit and confidence intervals for plasma ACTH in each geographic location using the ASVCP reference interval (RI) guidelines, for individual months and monthly groupings for 12 consecutive months.

Results: Plasma endogenous ACTH concentrations demonstrated a circannual rhythm. The increase in endogenous ACTH was not confined to the autumnal months but was associated with changes in photoperiod. During the quiescent period, plasma ACTH concentrations were lower, \( < 43 \) pg/mL (upper limit of the 90% confidence interval [CI]) in horses from Perth and \( \geq 67 \) pg/mL (upper limit of the 90% CI) in horses from Townsville, than at the acrophase, \( \geq 94 \) pg/mL (upper limit of the 90% CI) in horses from Perth, \( \leq 101 \) pg/mL (upper limit of the 90% CI) in horses from Townsville.

Conclusions and Clinical Importance: Circannual rhythms of endogenous ACTH concentrations vary between geographic locations, this could be due to changes in photoperiod or other unknown factors, and upper reference limits should be determined for specific locations.

Key words: ACTH; Horse; Photoperiod; Reference limit.

Measurement of endogenous ACTH in plasma is the most frequently used screening test to diagnose the common equine endocrinopathy pituitary pars intermedia dysfunction (PPID). Seasonal variation of plasma concentration of this hormone in clinically normal horses and horses with PPID is well recognized, with higher autumnal plasma ACTH concentrations in both the Northern and Southern Hemispheres. The variation in plasma ACTH concentration in healthy horses could be reflective of a circannual rhythm related to changing photoperiod.

Upper reference limits of plasma ACTH concentration have been determined by examination of individual horses, with plasma ACTH measured at a single time point. There are a number of studies that have longitudinally evaluated clinically normal horses over a 12-month period; however, these studies have not had sufficient sample size to generate an upper reference limit.

The first objective of the study was to longitudinally determine monthly upper reference limits for plasma concentration of ACTH in 2 disparate locations within Australia. The second objective was to examine whether geographic location within Australia affected the circannual rhythm of plasma concentration of ACTH in the 2 groups of clinically normal horses over a 12-month period.

Materials and Methods

The upper reference limit for plasma ACTH was determined using the American Society of Veterinary Clinical Pathology (ASVCP) RI guidelines.

Study Population

Horses were selected at each of 2 geographic locations within Australia; Perth in southern Australia (31°57’S, 115°52’E) and...
Townsville in northern Australia (19°26’S, 146°811E). The study population was recruited from 4 properties at each location. A thorough clinical examination was performed on all candidates, and horses were only included if they did not have any clinical signs consistent with PPID and were less than 20 years of age. Ethics approval was obtained from Murdoch University Animal Ethics Committee (Approval number R2702/14) and James Cook University Animal Ethics Committee (Approval number A2127).

Sample Collection

Sample collection began in March 2015 and ended in February 2016. Before each sample collection, all horses had physical examinations, including body condition scoring,11 palpation of fore feet digital pulses, walking and turning in a tight circle in both directions. Any horse that had an increased digital pulse or was hesitant on turning had a hoof tester examination. Horses were sampled in their own environment, either in their paddocks or when they came into the yard for routine activities. Horses were all sampled in the morning (within 2 hours of each individual horse’s previous sample collection) in the middle of each month. Blood was collected from the left jugular vein through a 20-g 1.5-inch vacutainer needle into evacuated 4-mL plastic tubes containing EDTA and evacuated 4-mL plastic plain tubes.5 The samples collected into tubes containing EDTA were placed on ice within 1 minute of collection and were centrifuged within 4 hours in a refrigerated centrifuge at 4000 × g for 5 minutes. Plasma and serum were aliquoted and placed into plastic vials5 and stored in a −80°C freezer until batch sample processing 1–12 months later. Data on day length at each location were gathered from Geoscience Australia.6 A subset of horses in each location had a TRH stimulation test as previously described, to further support case selection based on clinical normality.12

ACTH Analysis and Quality Control

Frozen plasma samples were transported on dry ice, and plasma ACTH concentrations analyzed using an Immulite 1000 ACTH solid-phase, 2-site sequential, chemiluminescent immunometric assay7 performed on an Immulite 1000 analyzer8 at IDEXX laboratories.9 The analytical sensitivity of the assay is 9 pg/mL.7 Quality control materials provided by the manufacturer were used daily (Immulite ACTH control module). The coefficients of variation for lower (29 pg/mL) and upper (414 pg/mL) level quality control materials were 4.16% and 5.07%, respectively, and were deemed acceptable.8

Statistical Analysis

Monthly data were tested for normality using the Shapiro-Wilk test and log-transformed if normality was not met. Outliers were identified by both the Tukey and the Reed method and were removed if determined to be aberrant observations. An aberrant observation was defined as a plasma ACTH value that was not comparable to the months preceding and after in that individual horse when all other monthly values for that horse were comparable to the rest of the group. Reference intervals and confidence intervals (CI) for plasma ACTH were calculated using parametric methodology by the software package R-studio9 and robust methodology by MedCalc 16.4.3 software.1 Statistical significance was assumed when P ≤ 0.05.

Repeated measures ANOVA with Bonferroni’s correction was used to determine differences in plasma ACTH over each individual month. When monthly means were not statistically different from each other, they were grouped and linear mixed modeling was used to determine the means and standard deviations to be representative of each group. Reference intervals were determined using the mean ± 2 standard deviations as the upper and lower reference limits, respectively, and 90% CI were obtained for the upper and lower reference limits.

Results

The final study cohort in Perth included 40 horses; the age range of horses was 4–15 years with an average and median age of these horses being 10.3 and 10.5 years, respectively. For 31 horses, samples were available for 12 months, with 9 horses having samples available over 11 months. Horse breeds were mixed and included Thoroughbreds (n = 11), Standardbreds (n = 12), Warmbloods (n = 3), mixed breeds (n = 6), and ponies (n = 8); there were 26 geldings and 14 mares. Thirty-eight horses were kept in paddocks and received supplemental feed of either roughage only or grain and roughage depending on their level of physical activity. Two horses were stabled at night and paddocked during the day for the majority of the study. All horses received routine anthelmintic care; vaccination status was unknown.

The final study cohort in Townsville included 41 horses, with an age range of 3–19 years; the average and median age of these horses was 11.6 years and 12 years, respectively. For 35 horses, samples were available for 12 months, with 6 horses having samples available over 11 months. There were 37 mares, 3 geldings, and 1 stallion. Breeds represented were Thoroughbreds (n = 23), Standardbreds (n = 7), Quarter Horses (n = 4), Australian Stock Horses (n = 6), and Warmblood horses (n = 1). All horses in the Townsville cohort were paddock housed and received supplemental feed of roughage only or grain and roughage depending on their level of physical activity. All horses received routine anthelmintic care and were vaccinated against tetanus and Hendra virus.

For the duration of the study, on intermittent occasions, individual horses in both cohorts had transient variations in foot related physical examination variables; however, no horse developed laminitis or other clinical signs consistent with PPID. For those individual horses that undertook some form of exercise in the preceding 24 hours, it was not deemed to be excessive. No horse was determined to be unwell on the day of sample collection.

Perth Data

Normality was not met, and monthly data were log-transformed to meet a Gaussian distribution. This was achieved for all months except July. Three outliers from different horses were removed from the data set; 2 from April (120 pg/mL and 138 pg/mL) and 1 from September (79.7 pg/mL). The outliers were considered to be unusual values as plasma ACTH in the months preceding and after were comparable to the rest of the group. The range and median plasma ACTH values (pg/mL) of each of these horses after outlier removal were 23.0–63.5 (31.8), 15.4–63.4 (28.4), and 23.3–62 (35.1), respectively. Additionally, 2 of the 3 horses with outlier values
had a TRH stimulation test performed and the plasma ACTH did not exceed concentrations after stimulation recommended by the equine endocrinology group. Laboratory error in December resulted in 6 samples being excluded that month and 3 horses were unavailable for collection in January. Sample sizes for each month were 40 with the exception of September (n = 39), December (n = 34), January (n = 37), and April (n = 38). Summary of data is presented in Table 1 (median, maximum, and minimum values). Upper reference limits and 90% CI are presented in Table 2. Confidence interval width compared to reference limit width ranged from 0.33 to 0.49.

The repeated measures ANOVA with Bonferroni’s correction suggested groupings of: June to November; December, January, and May; and February to April. Each of these groups was then analyzed using linear mixed modeling which more accurately accounts for between and within subject (horse) variation, to determine mean plasma ACTH concentrations to represent the groups and months within each group. For the first group, when June was compared with July (P = 0.186), August (P = 0.468), September (P = 0.576), October (P = 0.312), and November (P = 0.065), there was no significant difference in mean plasma ACTH concentrations. For the second grouping, when the month of January was compared to May there was no significant difference (P = 0.552); when compared to December (P = 0.843), the means were significantly different. For the third grouping, when the month of April was compared to March there was no significant difference (P = 0.172); when compared to February (P = 0.014), the means were significantly different. Although groups 2 and 3 did not achieve complete statistical homogeneity when analyzed using linear mixed modeling, they did so using repeated measures ANOVA and from a biological perspective these groupings were deemed valid. The upper reference limits and 90% CI were determined for each grouping (Table 3). Confidence interval width compared to reference limit width in the grouped data ranged from 0.14 to 0.22.

**Townsville Data**

Normality was not met, and monthly data were log-transformed to meet a Gaussian distribution. This was achieved for all months except August, September, and December. Six outliers from different horses were removed from the data set; 1 sample from November (185.0 pg/mL), December (104.0 pg/mL), and January (101.0 pg/mL), and 3 from February (101.0 pg/mL, 113.0 pg/mL, 200.0 pg/mL). The outliers were considered to be unusual values as plasma ACTH in the months preceding and after were comparable to the rest of the group. The range and median plasma ACTH values (pg/mL) of each of these horses after outlier removal were as follows: 41.90–88.10 (60.8), 31.20–60.80 (39.3), 25.4–63.9 (36.5), 23.6–87.5 (41.6) 29.5–89.9 (48.8), 14.4–43.4 (27.7), respectively. Additionally, 3 of the 6 horses with outlier values had a TRH stimulation test performed and the plasma ACTH did not exceed concentrations after stimulation recommended by the equine endocrinology group. Laboratory error or horses being unavailable for collection resulted in 2 samples being excluded for the month of January, and 1 sample being excluded from August, September, October, and February. Sample size was 41 for March-July, 40 for August-December, 38 for January, and 37 for

### Table 1. Plasma ACTH concentrations from the raw data used to generate reference intervals before log transformation from the Perth cohort.

| Month   | Median ACTH concentration (pg/mL) (range), n |
|---------|---------------------------------------------|
| July    | 21.40 (15.30–44.50), 40                     |
| August  | 23.40 (10.30–41.40), 40                     |
| September | 21.60 (12.40–33.70), 39                |
| October | 24.20 (13.80–38.70), 40                     |
| November | 25.40 (16.00–44.30), 40                |
| December | 27.80 (16.50–53.30), 34                    |
| January | 28.40 (19.20–59.60), 37                     |
| February | 36.10 (19.60–70.30), 40                |
| March   | 44.65 (23.00–80.50), 40                     |
| April   | 40.55 (28.50–67.60), 38                     |
| May     | 29.80 (16.30–68.00), 40                     |
| June    | 23.30 (14.80–49.50), 40                     |

### Table 2. Plasma ACTH upper reference values (90% CI) using parametric and robust methodology for the samples from horses in Perth.

| Month   | Plasma ACTH (pg/mL) Parametric (90% CI) | Robust (90%CI) |
|---------|------------------------------------------|----------------|
| July    | *                                        | 34.37 (30.20–39.91) |
| August  | 42.30 (32.23–48.06)                      | 41.89 (35.59–49.71) |
| September | 35.65 (32.15–39.53)                     | 36.37 (31.68–40.15) |
| October | 37.72 (34.17–41.65)                      | 38.56 (34.78–42.32) |
| November | 41.68 (37.21–46.69)                     | 41.46 (37.06–46.72) |
| December | 48.48 (42.62–55.14)                     | 46.72 (42.41–56.33) |
| January | 53.86 (47.12–61.56)                      | 56.33 (49.95–62.25) |
| February | 68.70 (59.83–78.89)                     | 69.93 (60.36–79.48) |
| March   | 81.97 (71.60–93.86)                      | 83.20 (71.12–94.47) |
| April   | 65.38 (58.93–72.53)                      | 64.82 (57.06–73.13) |
| May     | 54.70 (48.13–62.17)                      | 53.89 (45.74–62.78) |
| June    | 40.21 (35.49–45.35)                      | 40.38 (35.79–45.33) |

*Data not normally distributed after log transformation therefore parametric analysis not applicable.
  CI, Confidence interval.

### Table 3. Plasma ACTH upper reference values with 90% CI using grouped data from horses sampled in Perth.

| Month               | Upper reference values (pg/mL) (90% CI) |
|---------------------|----------------------------------------|
| June–November       | 41.12 (39.3–43.01)                     |
| May/December/January| 52.51 (48.77–56.54)                    |
| February–April      | 78.18 (72.72–84.04)                    |

CI, Confidence interval.
February. Summary of data is presented in Table 4 (median, maximum, and minimum values). Upper reference limit and 90% CI are presented in Table 5.

### Table 4. Plasma ACTH concentrations from the raw data used to generate reference intervals before log transformation from the Townsville cohort.

| Month   | Median ACTH concentration (pg/mL) (range), n |
|---------|---------------------------------------------|
| July    | 30.60 (19.00–59.50), 41                     |
| August  | 33.25 (12.10–88.10), 40                     |
| September | 30.30 (20.60–79.10), 40                |
| October | 23.35 (10.70–61.40), 40                     |
| November | 24.00 (10.50–49.90), 40                  |
| December | 20.95 (19.30–82.90), 40                  |
| January | 34.95 (21.00–78.00), 38                     |
| February | 40.90 (27.20–75.90), 37                    |
| March   | 48.60 (31.00–99.80), 41                     |
| April   | 34.70 (18.10–66.30), 41                     |
| May     | 34.30 (18.90–79.90), 41                     |
| June    | 29.70 (17.80–60.80), 41                     |

*Data not normally distributed after log transformation therefore parametric analysis not applicable.
CI, Confidence interval.

### Table 5. Plasma ACTH upper reference values (90% CI) using parametric and robust methodology for the samples from horses in Townsville.

| Month   | Plasma ACTH (pg/mL) | Robust (90% CI) |
|---------|---------------------|-----------------|
| July    | 50.76 (45.07–56.60) |                 |
| August  | 62.66 (54.16–72.48) | 62.25 (50.74–75.61) |
| September | 60.34 (49.41–70.80) | 60.34 (49.41–70.80) |
| October | 44.40 (37.00–52.85) | 44.40 (37.00–52.85) |
| November | 56.48 (45.12–68.42) | 56.48 (45.12–68.42) |
| December | 45.69 (37.95–55.25) | 45.69 (37.95–55.25) |
| January | 77.21 (62.02–91.64) |                 |
| February | 76.35 (64.88–87.14) | 76.35 (64.88–87.14) |
| March   | 88.87 (77.49–101.34) | 88.87 (77.49–101.34) |
| April   | 73.38 (60.24–86.09) |                 |
| May     | 67.18 (56.26–80.11) |                 |
| June    | 49.45 (43.46–56.26) |                 |

### Discussion

This study generated individual normal upper reference limits for plasma ACTH concentration for each month of the year and specific monthly groupings in 2 geographic locations within the Southern Hemisphere. This study differs from previous studies in that sufficient individual clinically normal horses were longitudinal tracked monthly over a 12-month period to generate monthly upper reference limits and confidence intervals. Endogenous ACTH in this study had a circannual rhythm, consistent with other studies. The increase in plasma ACTH was not confined to only the autumnal months as has been previously described but was consistent with the change in photoperiod as has been described by Durham.

The generation of veterinary reference limits should follow specific guidelines, and within this study, the ASVCP guidelines were used. Although it was the intention to utilize a sample size of 40 horses for each month, this was not possible. As all sample sizes were greater than 20 and as plasma ACTH concentrations of most months were considered Gaussian in their distribution after transformation, both robust and parametric methodologies were performed to determine the
Reference limits and median, maximum, and minimum plasma ACTH values are presented (Tables 1 and 4). Two methodologies were employed as similarity in RI, as was demonstrated in this case, supports a homogenous population. Reference intervals are essential to assist a clinician in making a clinical decision regarding the presence or absence of disease. Reference limits only describe the variability of the measured analyte within a population of normal animals and the value at which the analyte should be considered normal in the general population is not below the upper reference limit, but can be considered to be below the upper limit of the CI. Confidence intervals were calculated for all months by both the parametric and robust methodologies and were found to be similar (Tables 2 and 5). The CI widths compared to the width of the RI for all months in both data sets exceeded 0.2; the recommendation suggested by the ASVCP. This is not surprising given these criteria cannot be met with a sample size of less than 55. When monthly data were grouped, the CI widths compared to the width of the RI were ≤0.2. When assessing analytes where there is a pronounced difference between health and disease, as has been shown in particular with autumnal plasma ACTH concentrations in horses with clinical signs of PPID, higher imprecision around the upper reference limit should not affect clinical interpretation.

Two distinct periods were identified within the circannual rhythm of endogenous ACTH. A period when the upper reference limit for plasma ACTH was lower compared to the rest of the year with little variability and is defined by the authors as the “quiescent phase.” This was June to November (6 months) inclusive in Perth as these months were statistically homogenous. In Townsville, the quiescent period might be from April to December (9 months) as suggested by statistical analysis; however, it is possible it follows a similar pattern to Perth (Fig 1), which only might become evident with larger sample sizes or investigation with other endocrine tests such as monthly TRH stimulation testing. A second period commences when plasma ACTH begins to increase, reaches a peak (acrophase), and then declines, this period has been defined by the authors as the “dynamic phase.” The upper reference limits during this phase were higher and more variable. Geographic location appeared to influence the length of the dynamic ACTH phase with a potentially longer dynamic phase the further south the location. In both locations, the plasma ACTH upper reference limit was similar at the acrophase (March in both locations) and coincided with the autumn equinox. The authors surmised the greater the change in circannual photoperiod the lower the upper reference limit of plasma ACTH during the quiescent phase with a potentially longer dynamic phase of ACTH. This is supported by the upper reference limit of plasma ACTH in Perth during the quiescent period being lower than in Townsville during the quiescent period.

Due to the monthly variation during the dynamic phase, grouping of the data was problematic. In Perth, 2 of the groupings chosen, February to April inclusive and December, January, and May did not display complete statistical homogeneity within the groups; however, these 2 groupings were maintained from a clinical perspective.
decision-making perspective as there was little difference in the upper reference limits suggesting biological similarity. It is up to the individual clinician to determine whether they wish to use a monthly CI upper limit or a grouped CI upper limit. In Townsville, plasma ACTH concentrations during the dynamic phase did not display any statistical homogeneity and as such clinicians are recommended to use a monthly CI upper limit for that period. Plasma ACTH concentrations were lower in June, October, and November within the proposed quiescent period of April to December; the clinical relevance of this is unknown; hence, individual clinicians should determine whether they wish to use the higher CI upper limit for the grouped months (July, August, September, December, April, and May) from April to December inclusive or use monthly CI upper limits.

Although a cutoff value of plasma ACTH in clinically normal horses for a latitude between the 2 locations of this study has been reported, samples were collected from horses at a single time point, data were grouped into seasons, and a differing statistical methodology was used; therefore, it is difficult to compare the 2 studies. Within that study, the cutoff value for both the autumnal and nonautumnal periods was lower than either the Perth or Townsville limit of the upper CI. The authors are of the opinion that this is not due to case selection criteria as this study used younger animals with no clinical signs of PPID where disease prevalence is lower, rather it is likely to be due to that study’s use of an alternate statistical methodology.

Although the limit of the upper CI for plasma ACTH during the dynamic phase in both Australian locations was similar to what has been reported in the Northern Hemisphere, the limit of the upper CI for the quiescent phase in the Northern Hemisphere. This might be due to study design or the probability that local geographic and management factors have a combined effect with photoperiod in determining regulation of ACTH secretion. It must be acknowledged that if plasma ACTH concentrations exceed the limit of the upper CI, there is uncertainty as to whether endogenous ACTH in horses has the disease. Clinical decision limits, that is the value at which it is likely the animal has the disease, differ from reference limits and are usually based on guidelines reached from a group consensus of expert individuals. With regard to PPID, guidelines regarding clinical decision limits continue to be reviewed, particularly in the Southern Hemisphere, as further research is conducted.

The selection criteria used to choose horses were similar to previous studies with both age and the absence of clinical signs associated with PPID guiding the inclusion of horses. The inadvertent inclusion of subclinical PPID was thought to be unlikely in this study as a subset of horses had TRH stimulation tests during the quiescent ACTH phase and were determined to be normal (unpublished data). In addition, prevalence of the disease is low in younger horses and horses were sampled on multiple occasions so that if persistently increased levels were detected suggestive of PPID they could be excluded. Age does not affect plasma ACTH concentration in healthy horses and as such the benefits of using a younger population with a lower prevalence of disease were thought to outweigh the risk of inadvertent inclusion of horses with subclinical disease had an older population been used.

Similar to other studies determining the upper limit of plasma ACTH or the effect of location, sex was not standardized across locations as sex does not affect plasma ACTH in equids. However, because at one time point on collection days as paired or multiple samples have not been shown to confer a benefit over a single measurement. Although the literature is conflicting as to whether endogenous ACTH in horses has a well-defined circadian rhythm, all samples were collected within the same 2-hour time period each month to ensure consistency.

On several occasions, isolated unusual plasma ACTH increases were detected that exceeded the upper reference limit for that time of year, predominantly during the ACTH dynamic phase when increased variability would be appreciated. Within this study, it is unknown why the isolated unusual increases occurred could not be provided as the horses were in good health and had not been subjected to perceptible physiological stress, which has been implicated in increasing plasma ACTH concentrations in horses. These findings support the notion that if a single plasma ACTH test is being used to screen for PPID, interpretation should be taken in light of clinical presentation and repeat testing or performing a TRH stimulation test might be preferable over initiation of treatment.

Limitations of this study are that horses were only evaluated longitudinally for 12 months and the assumption is made that the 12-month period chosen is representative of the circannual rhythm; however, it is unknown whether this is the case. Secondly as this was not a terminal study, it is unknown whether these horses had subclinical PPID; however, this limitation is shared with many other studies evaluating plasma ACTH in clinically normal horses. Finally, ideally the horses would have been breed matched across each location with only 1 breed utilized as although previous work has suggested that there is no difference in plasma ACTH between ponies and horses, emerging literature suggests ACTH might differ between breeds.

In conclusion, this study achieved the aims of determining monthly RIs for 2 disparate locations within Australia. We demonstrated that the circannual rhythm is characterized by a quiescent phase where the upper reference limit of plasma ACTH is lower and variable between locations, but higher than those currently reported for horses. In comparison, there is a dynamic ACTH phase which results in a similar acrophase at the autumn equinox in both locations and the Northern Hemisphere. In Australia at locations closer to the equator, horses might have a shorter dynamic phase to their circannual ACTH rhythm with higher reference limits during the quiescent phase.
Footnotes

a Greiner Bio-One 4 mL plastic whole blood tube with spray coated K2EDTA, reference number 454023, Germany
b Greiner Bio-One 4 mL plastic whole blood tube with serum clot activator, reference number 454204, Germany
c Cryo,S® cryovials, Greiner Bio-One GmbH, Germany
d Geo Science Australia http://www.ga.gov.au/
e Siemens Immulite/Immulate 1000/ACTH assay, Australia
f IDEXX Laboratories Pty Ltd, Unit 6, 38 – 46 South St, Rydalmere NSW 2116 Australia

© The Royal College of Pathologists of Australasia and the Australasian Clinical Biochemist Association Quality Assurance Program

r R Studio Team (2015). R Studio: Integrated Development for R. R Studio, Inc., Boston, MA URL http://www.rstudio.com/

j MedCalc Software bvba, Mariakerke, Belgium; https://www.medcalc.org; 2016

Acknowledgments

MUVH institutional herd, Zia Park (Ms Gail Simms), Oriel Park (Ms Alana Dodds), Claremont therapeutic riding school (Ms Missi Henry). JCU institutional herd, Townsville Veterinary Clinic, Mr Laurie Reilly. Peter Verwoerd and Louise Camilleri (IDEXX Laboratories, Australia).

Conflict of Interest Declaration: Crissy Secombe and Rachel Tan have received research funding, travel allowances, speaking honorariums, provided unpaid consulting and sit on an advisory board for Boehringer Ingelheim. David Byrne has received research funding from Boehringer Ingelheim.

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

References

1. Couëtil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996;10:1–6.
2. Van Der Kolk JH, Wensing T, Kalsbeek HC, Breukink HJ. Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domest Anim Endocrin 1995;12:35–39.
3. Copas VE, Durham AE. Circannual variation in plasma adrenocorticotropin hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction. Equine Vet J 2012;44:440–443.
4. Frank N, Elliott SB, Chameroy KA, et al. Association of season and pasture grazing with blood hormone and metabolite concentrations in horses with presumed pituitary pars intermedia dysfunction. J Vet Intern Med 2010;24:1167–1175.
5. McGowan TW, Pinchbeck GP, McGowan CM. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses. Equine Vet J 2013;45:74–79.
6. Durham AE. Further observations of seasonality of pars intermedia secretory function in 30,000 horses and ponies. Dorothy Russell Havemeyer Foundation 3rd equine endocrine summit. Middleburg, Virginia, November 12-20 2014:11.
7. Funk RA, Stewart AJ, Wooldridge AA, et al. Seasonal changes in plasma adrenocorticotropin hormone and alpha-melanocytestimulating hormone in response to thyrotropin-releasing hormone in normal, aged horses. J Vet Intern Med 2011;25:579–585.
8. Beech J, Boston RC, McFarlane D, Lindborg S. Evaluation of plasma ACTH, alpha-melanocytestimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction. J Am Vet Med Assoc 2009;235:715–722.
9. Place NJ, McGowan CM, Lamb SV, et al. Seasonal variation in serum concentrations of selected metabolic hormones in horses. J Vet Intern Med 2010;24:650–654.
10. Friedrichs KR, Harr KE, Freeman KP, et al. ASVCP reference interval guidelines: Determination of de novo reference intervals in veterinary species and other related topics. Vet Clin Path 2012;41:441–453.
11. Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score, physical measurements and body fat percentage in mares. Equine Vet J 1983;15:371–372.
12. Beech J, Boston R, Lindborg S, Russell GE. Adrenocorticotropic hormone concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia. J Am Vet Med Assoc 2007;231:417–426.
13. Frank N, Andrews FM, Durham A, et al. Recommendations for the diagnosis and treatment of pituitary pars intermedia dysfunction (PPID). Equine Endocrinology Group (Internet) 2015:4–5. (Cited 2016 Nov 1). Available from: https://sites.tufts.edu/equineendogroup/files/2015/12/2015-10-16_EEG-2015-recommendations.pdf.
14. Donaldson MT, McDownell SM, Schanbacher BJ, et al. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med 2005;19:217–222.
15. Lee ZY, Zylstra R, Hartiou SJ. The use of adrenocorticotropic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses. Vet J 2010;185:58–61.
16. Diez De Castro E, Lopez I, Cortes B, et al. Influence of feeding status, time of the day, and season on baseline adrenocorticotropic hormone and the response to thyrotropin releasing hormone-stimulation test in healthy horses. Domest Anim Endocrin 2014;48:77–83.
17. Horn PS, Pesce AJ, Copeland BE. Reference interval computation using robust vs parametric and nonparametric analyses. Clin Chem 1999;45:2284–2285.
18. Braun JP, Concordet D, Gelfre A, et al. Confidence intervals of reference limits in small reference sample groups. Vet Clin Path 2013;42:395–398.
19. Petersen PH, Jensen EA, Brandslund I. Analytical performance, reference values and decision limits. A need to differentiate between reference intervals and decision limits and to define analytical quality specifications. Clin Chem Lab Med 2012;50:819–831.
20. McFarlane D, Paradis MR, Zimmel D, et al. The effect of geographic location, breed, and pituitary dysfunction on seasonal adrenocorticotropic and alpha-melanocytestimulating hormone plasma concentrations in horses. J Vet Intern Med 2011;25:872–881.
21. Grubbs S, Neal D, Keefe T. Epidemiological characteristics of horses with PPID at initial diagnosis. J Vet Intern Med 2015;29:1231.
22. Marr CM, Mair TS. EVE and EVJ online collection of equine endocrinology: Recent and future directions; a great start, but still a long way to go. Equine Vet J 2014;46:97–98.
23. McFarlane D, Sellon DC, Gaffney D, et al. Hematologic and serum biochemical variables and plasma corticosteroid concentrations in healthy aged horses. Am J Vet Res 1998;59:1247–1251.
24. Rendle DI, Duz M, Beech J, et al. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses. J Vet Intern Med 2015;29:355–361.
25. Rendle DI, Litchfield E, Heller J, Hughes KJ. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction. Equine Vet J 2014;46:113–117.
26. Fazio E, Medica P, Aronica V, et al. Circulating beta-endorphin, adrenocorticotropic hormone and cortisol levels of stallions before and after short road transport: Stress effect of different distances. Acta Vet Scand 2008;50:6.
27. Cravana C, Medica P, Prestopino M, et al. Effects of competitive and noncompetitive showjumping on total and free iodothyronines, ß-endorphin, acth and cortisol levels of horses. Equine Vet J 2010;42:179–184.
28. Durham A, Shreeve S. Horse-factors influencing the seasonal increase in plasma ACTH secretion. Dorothy Russell Have-meyer Foundation International Equine Endocrinology Summit, Coral Gables, Florida. January 3-7 2017:36–37.